Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Adaptimmune Therapeutics plc Announces Registered Direct Offering of American Depositary Shares | ||
By: Nasdaq / GlobeNewswire - 05 Sep 2018 | Back to overview list |
|
PHILADELPHIA and OXFORD, United Kingdom, Sept. 05, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (“Adaptimmune”) (Nasdaq: ADAP), a leader in T-cell therapy to treat cancer, today announced that it has entered into a definitive agreement with Matrix Capital Management Company, LP (“Matrix”), New Enterprise Associates 16, L.P., New Enterprise Associates 14, L.P. (“NEA”) and Syncona Portfolio Limited (“Syncona”), to purchase an aggregate of US$100 million of its American Depositary Shares (“ADSs”) in a registered direct offering. The transaction was completed from the company’s shelf registration at a price of $10.00 per ADS. The closing of this offering is expected to take place on or about September 7, 2018, subject to the satisfaction of customary closing conditions. Net proceeds of the offering will be used to advance the company’s wholly owned pipeline of SPEAR T-cell candidates through clinical trials as well as for other general corporate purposes. “This financing strengthens our balance sheet and extends our runway through to late 2020. This gives us strategic flexibility as we enter a potentially transformative period of data from our wholly-owned pipeline,” said James Noble, Adaptimmune’s CEO. “I want to welcome Syncona to our shareholder base as they join NEA and Matrix in this round. We are delighted to receive this support from our key shareholders as we continue building an integrated cell therapy company.” A shelf registration statement on Form S-3 relating to the public offering of the ADSs described above was filed with the Securities and Exchange Commission (“SEC”) and became effective on July 12, 2018. The offering was made only by means of a written prospectus and prospectus supplement that form a part of the registration statement. The prospectus supplement and accompanying prospectus relating to the offering contain important information relating to the ADSs. The prospectus supplement will be filed with the SEC and will be available on the SEC’s website at http://www.sec.gov, or may be obtained, when available, by contacting Adaptimmune Therapeutics plc, Attn: Investor Relations, 351 Rouse Boulevard, Philadelphia, PA 19112, or by telephone at: (215) 825-9310. This press release shall not constitute an offer to sell nor the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. This offering may only be made by means of a prospectus supplement and related base prospectus. For readers in the European Economic Area For readers in the United Kingdom About Adaptimmune Forward-Looking Statements Adaptimmune Contacts: Investor Relations: |
||
|
||
Copyright 2018 Nasdaq / GlobeNewswire | Back to overview list |